P
ProQR Therapeutics N.V. (PRQR)
NCM – Real Time Price. Currency in USD
1.60
-0.01 (-0.62%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
1.60
-0.01 (-0.62%)
At close: May 12, 2026, 4:00 PM EDT
ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic diseases. The company also develops AX-2402, which targets methyl CpG binding protein 2 mutations for Rett syndrome; AX-2911, which targets PNPLA3 for metabolic dysfunction-associated steatohepatitis; and AX-1412, which targets the B4GALT1 gene for cardiovascular diseases. It has a research and collaboration agreement with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
| Name | Position |
|---|---|
| Dr. Cristina Lopez Lopez M.D., Ph.D. | Chief Medical Officer |
| Dr. Gerard Platenburg Ph.D. | Co-Founder, Chief Scientific Officer & Executive Director |
| Mr. Daniel Anton de Boer | Founder, CEO & Executive Director |
| Mr. Dennis Hom | Chief Financial Officer |
| Ms. Sandra van der Kolk | Junior Financial Controller |
| Ms. Sarah Cue Kiely | Vice President of Investor Relations & Corporate Communications |
| Ms. Sheila Sponselee | Chief People & Operations Officer |
| Date | Type | Document |
|---|---|---|
| 2026-05-12 | 6-K | prqr-20260331x6k.htm |
| 2026-05-04 | 6-K | tm2613307d1_6k.htm |
| 2026-04-08 | 6-K | tm2611275d1_6k.htm |
| 2026-03-25 | 6-K | tm269800d1_6k.htm |
| 2026-03-12 | 6-K | tm268100d2_6k.htm |
| 2026-03-12 | 20-F | prqr-20251231x20f.htm |
| 2026-02-09 | 6-K | tm265494d1_6k.htm |
| 2026-01-08 | 6-K | tm262448d1_6k.htm |
| 2025-11-06 | 6-K | prqr-20250930x6k.htm |
| 2025-11-03 | 6-K | tm2529990d1_6k.htm |